Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform

We herein report the development and evaluation of a novel HER2-targeting antibody–drug conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our hydrophilic monodisperse polysarcosine (PSAR) drug-linker platform (PSARlink). In vitro and in vivo experiments were conducted in...

詳細記述

書誌詳細

出版年:	Pharmaceuticals
主要な著者:	Louise Conilh, Guy Fournet, Eric Fourmaux, Angélique Murcia, Eva-Laure Matera, Benoît Joseph, Charles Dumontet, Warren Viricel
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2021-03-01
主題:	antibody–drug conjugates polysarcosine deruxtecan topoisomerase I inhibitor camptothecin
オンライン･アクセス:	https://www.mdpi.com/1424-8247/14/3/247